Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 24448 in Major Depressive Disorder
NCT00262665Phase 2Withdrawn
- Start
- Mar 2005
- Primary completion
- Mar 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of farampator in major depressive disorder (MDD). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Planned start Mar 2005; status: withdrawn.
02
Drugs
farampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00262665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262665.